CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

How pCODR Works

CADTH operates two pan-Canadian drug review processes: the CADTH pan-Canadian Oncology Drug Review (pCODR), which deals specifically with cancer drugs, and the CADTH Common Drug Review (CDR), which deals with other drugs.

Both pCODR and CDR are designed to bring consistency and clarity to the assessment of drugs in Canada by reviewing clinical, economic, and patient evidence, and using this information to make non-binding recommendations to Canada’s public drug plans to support their drug funding decisions.